Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 22722 29TH DR. SE, SUITE 100 SEATTLE WA 98021 |
Tel: | 1-404-736-3838 |
Website: | achievelifesciences.com |
IR: | See website |
Key People | ||
Richard Stewart Executive Chairman of the Board | Cindy Jacobs President, Director, Chief Medical Officer | John A. Bencich Chief Executive Officer, Director | Jerry Wan Principal Accounting Officer |
Business Overview |
Achieve Life Sciences, Inc. is a late-stage clinical pharmaceutical company engaged in the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence. The Company's product candidate, cytisinicline, is a naturally occurring, plant-based alkaloid. Cytisinicline is structurally similar to nicotine and has a well-defined, dual-acting mechanism of action that is both agonistic and antagonistic. Cytisinicline is a partial agonist that binds with high affinity to the alpha-4 beta-2, nicotinic acetylcholine receptors in the brain. Through its dual-acting partial agonist/partial antagonist activity, cytisinicline helps reduce nicotine cravings, withdrawal symptoms and reward and satisfaction associated with smoking. It is developing cytisinicline as an aid to smoking cessation and treatment for nicotine addiction to address the limitations of both prescription drugs and of over-the-counter (OTC) products. |
Financial Overview |
For the nine months ended 30 September 2023, Achieve Life Sciences Inc revenues was not reported. Net loss decreased 22% to $24.3M. Lower net loss reflects Research & Development decrease of 39% to $12.5M (expense), Interest income increase from $81K to $617K (income). Basic Earnings per Share excluding Extraordinary Items increased from -$3.23 to -$1.27. |
Employees: | 20 as of Dec 31, 2022 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $151.09M as of Sep 30, 2023 |
Annual revenue (TTM): | $0.00M as of Sep 30, 2023 |
EBITDA (TTM): | -$33.36M as of Sep 30, 2023 |
Net annual income (TTM): | -$35.57M as of Sep 30, 2023 |
Free cash flow (TTM): | -$31.26M as of Sep 30, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 34,251,911 as of Feb 28, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |